Pfizer launches later-stage study of pill to treat COVID-19
Pfizer on Wednesday announced that it had initiated a later-stage clinical trial for a pill that could potentially treat COVID-19.
If proven to be safe and effective, the drug could fill an unmet need for a widespread, easier-to-use treatment, as opposed to an infusion like remdesivir, another treatment.
Pfizer is beginning a trial that will enroll 1,140 participants, the company said.
The drug could eventually be used in a “broad” population of patients, Pfizer said, namely people who have symptomatic cases of COVID-19 and are not hospitalized or at risk of severe illness.
A separate trial began in July for people who are at risk of severe illness.
“Success against #COVID19 will likely require both vaccines & treatments,” Pfizer CEO Albert Bourla tweeted on Wednesday. “We’re pleased to share we’ve started a Phase 2/3 study of our oral antiviral candidate—specifically designed to combat SARS-CoV-2—in non-hospitalized, low-risk adults.”
Other drugmakers, including Roche and Merck, have also been studying treatments in this area.
“If successful, [the drug] has the potential to address a significant unmet medical need, providing patients with a novel oral therapy that could be prescribed at the first sign of infection, without requiring hospitalization,” Pfizer said in a news release.
The Food and Drug Administration last week gave full approval to the Pfizer-BioNTech COVID-19 vaccine, making it the first of the vaccines used in the U.S. to move beyond the emergency authorization stage.
Copyright 2023 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.